Session Type: Plenary
This plenary session examines the evolving landscape of Real-World Evidence (RWE) across the Asia Pacific region, where adoption varies significantly between countries despite growing interest. Speakers will explore how RWD/RWE is increasingly supporting decision-making in life sciences, regulatory approvals, and reimbursement. The session will highlight regional efforts while addressing critical challenges including data availability, data quality, interoperability, privacy concerns, and potential biases. Attendees will gain insights into how RWE can play a role in decision-making process and discover practical lessons for infrastructure development and capacity building specific to Asia Pacific healthcare environments.
The use of real-world evidence (RWE) continues to increase but has yet to reach its potential and maximize value. There is a long history of RWE in post-market reviews to monitor drug safety, effectiveness, and value-based pricing; however, RWE for decision-making such as drug approvals, health technology assessment and clinical practice remains in its development. Access to large – population level - real world databases is fundamental as is developing robust methods for standardized analysis of data and collaboration across jurisdictions remains in its infancy.
This plenary panel explores the future for RWE in HEOR and addresses questions around what do we, as HEOR experts, need to do to develop and optimize the use of RWE? How should we go about getting RWE into decision-making and clinical practice? What should we be doing to foster the development and use of RWE? Is there a place for using AI in RWE? If a harmonized HTA ecosystem was sought, can RW data and RWE provide the uplift needed to harmonize systems?
Bruce Crawford is the General Manager for North Asia at Vista Health, based in Tokyo Japan. He has over 30 years of global experience in health economics and outcomes research, Clinical Outcomes Assessments, epidemiology and generation of real-world evidence. Bruce has considerable expertise in health economic and outcomes evaluations, and helps clients link clinical and market data to further the successful development and marketing of their products. Bruce focuses on the generation of evidence required to demonstrate asset value and the navigation of regulatory and reimbursement hurdles.
Bruce has written and lectured on pharmacoeconomic and outcomes research methodologies and impacts on study validity. Bruce previously held appointments as Clinical Instructor of Epidemiology and Biostatistics at Tufts University School of Medicine, Adjunct Project Professor of Health Technology Assessment and Public Policy at Tokyo University Graduate School of Public Policy, Adjunct Instructor at Kyoto University, School of Medicine and Public Health in the Department of Pharmacoepidemiology and currently guest lectures at St Luke’s International Graduate School of Public Health.
